Search
Jeffrey A. Drebin, MD, PhD, has been named the new Chairman of the Department of Surgery at Memorial Sloan Kettering Cancer Center (MSK). Dr. Drebin brings to MSK decades of experience as a world-class surgical oncologist specializing in pancreaticobiliary, upper gastrointestinal and liver surgery. He joins MSK from the Perelman School of Medicine of the University of Pennsylvania (UPenn) where he was most recently the John Rhea Barton Professor and Chairman of the Department of Surgery. Dr. Drebin formally assumes his new role as Peter Scardino, MD, steps down as Chairman after ten years of visionary leadership.
In a new study, MSK researchers looked at why glioblastoma brain tumors usually come back after treatment. Their findings suggest that a subset of cells — cancer stem cells — are able to evade current treatments because they are not actively dividing, and that these cells later form new tumors.
MSK studies presented at the 2022 American Association for Cancer Research meeting include updates on a targeted therapy for lung cancer, lab research on combining statins with a breast cancer drug, and a new tool for diagnosing blood cancer.
Collaboration will enhance innovation and the adoption of AI in translational research with the goal of improving patient care and outcomes.
New MSK research identifies a gene mutation associated with resistance to breast cancer treatment; reports encouraging results for expanding use of a new prostate cancer radiotherapy; determines the best radiation level for avoiding complications treating spinal tumors; and finds that proton therapy is effective against previously treated head and neck cancers.
New research from MSK offers new proof-of-concept compounds against acute myeloid leukemia; reports results from a phase 1 clinical trial appraising two drugs against low- grade glioma; examines MSK’s first-in-the-nation program integrating herbal medicine into oncology care; and identifies how high-grade histologic patterns in lymph node metastases could better predict lung cancer outcomes.
In 2024, the MSK Giving community raised $511 million to advance MSK’s mission of ending cancer for life — every single dollar donated is making a real difference in the way we treat and understand cancer.
Developmental biologist Maria Jasin studies homologous recombination, which is important in DNA repair and can lead to cancer when it malfunctions.